samedan logo
 
 
 
spacer
home > ebr > spring 2003 > the biosaxony region
PUBLICATIONS
European Biopharmaceutical Review

The biosaxony Region

"There's one thing I am certain of... Saxony will soon be Germany's main biotechnology centre..." - Professor Guenter Blobel (Nobel Prize for Medicine, 1999)

Should every nation, state, city, town and village develop their own biotechnology cluster? What is biosaxony and how could it possibly be different from the many other bio-locations? As you read this article, hopefully you will agree that there are unique elements to biosaxony that justify taking a closer look. First there are the people; the ready availability of a highly trained and motivated workforce with (together with Portugal) the lowest labour rates in Europe. Rates will stay low as Eastern Europe opens up in 2004 and the availability of skilled labour is further supplemented.

Next there is the infrastructure - the most modern in Europe with 100 per cent digital communication systems and fibre-optic networks, gas, electricity and waste disposal functionality at green field locations, as well as modern roads, airports and rail networks which have all been rebuilt within the last 10 years.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Ivan Baines, Partner at Biopolis Consultants

Dr Baines received his PhD in Cell Biology and Biochemistry from University College London in 1988 and performed postdoctoral and independent research at the National Institutes of Health (USA). He then joined the National Heart, Lung and Blood Institute (NHLBI) to help administer its $2.8 billion budget for basic and clinical life sciences research.

While promoting the NHLBI's Small Business Innovation Research (SBIR) award programme, Dr Baines advised over 100 new start-ups within life sciences. He also helped turn the revenue balance of the NHLBI's patent portfolio from loss to profit in under two years. Dr Baines helped to set up and run the Max Planck Institute for Molecular Cell Biology and Genetics in Dresden as Scientific Co-ordinator and Director of Services and Facilities, before co-founding Biopolis Consultants in 2001.

spacer
Dr Ivan Baines
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Stability Testing and Forced Degradation Stress Tests - Proactive Risk Management

Whereas the durability of many consumables, have a strong tendency to decrease, stability is and remains a crucial factor for pharmaceuticals. That is why the identification and elimination of factors, which put long-term stability at risk, is central during development – and an important requirement concerning the product’s quality.
More info >>

White Papers

Planning the Execution of a Viral Clearance Study

Eurofins BioPharma Product Testing

Viral clearance studies are a necessary component of any regulatory submission for clinical trials or commercial product approval for all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove or inactivate viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise to perform. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house. When multiple parties are involved in this process, clear communication and a comprehensive understanding of the approach and timeline is critical.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement